Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -105.17% is 91% below its 5-year average of -54.94%, near the low end of its 5-year range (-105.17%–-44.61%).
As of the fiscal period ended Tuesday, June 30, 2026. 52.42% below its 12-month average of -69.00%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -105.17%.
RETURN ON INVESTED CAPITAL (ROIC)
-105.17%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-69.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-55.90%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-54.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.42%
CURRENT VS 3Y AVG
-88.12%
CURRENT VS 5Y AVG
-91.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-194.91%
vs the sector median at left
Zentalis Pharmaceuticals, Inc.
Market Cap
$190.07M
Return on Invested Capital (ROIC)
-105.17%
TTM Avg
-69.00%
3Y Avg
-55.90%
5Y Avg
-54.94%
Market Cap
$189.11M
Return on Invested Capital (ROIC)
-74.02%
TTM Avg
-48.91%
3Y Avg
-62.69%
5Y Avg
-47.07%
Market Cap
$192.49M
Return on Invested Capital (ROIC)
-20.24%
TTM Avg
-14.71%
3Y Avg
-27.01%
5Y Avg
-29.46%
Market Cap
$197.18M
Return on Invested Capital (ROIC)
-41.61%
TTM Avg
-54.73%
3Y Avg
-70.67%
5Y Avg
-64.43%
Market Cap
$182.60M
Return on Invested Capital (ROIC)
-51.01%
TTM Avg
-69.12%
3Y Avg
-59.60%
5Y Avg
-89.29%
Market Cap
$197.87M
Return on Invested Capital (ROIC)
-33.88%
TTM Avg
-37.38%
3Y Avg
-46.28%
5Y Avg
-37.99%
Market Cap
$198.33M
Return on Invested Capital (ROIC)
-33.10%
TTM Avg
-20.50%
3Y Avg
-16.94%
5Y Avg
-23.40%
Market Cap
$180.47M
Return on Invested Capital (ROIC)
-9.57%
TTM Avg
-477.38%
3Y Avg
-295.61%
5Y Avg
-295.61%
Market Cap
$179.75M
Return on Invested Capital (ROIC)
-46.59%
TTM Avg
-39.23%
3Y Avg
-33.74%
5Y Avg
-53.74%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $190.07M | -105.17% | -69.00% | -55.90% | -54.94% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -74.02% | -48.91% | -62.69% | -47.07% |
| RxSight, Inc. (RXST)vs › | $192.49M | -20.24% | -14.71% | -27.01% | -29.46% |
| Surrozen, Inc. (SRZN)vs › | $197.18M | -41.61% | -54.73% | -70.67% | -64.43% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | -51.01% | -69.12% | -59.60% | -89.29% |
| Exagen Inc. (XGN)vs › | $197.87M | -33.88% | -37.38% | -46.28% | -37.99% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | -33.10% | -20.50% | -16.94% | -23.40% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -9.57% | -477.38% | -295.61% | -295.61% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | -46.59% | -39.23% | -33.74% | -53.74% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | -3.21% | -7.29% | -11.96% | -13.56% |
ROIC
-105.2%
ROE
-121.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -105.17% |
| 2026-03-31 | -65.38% |
| 2025-12-31 | -59.63% |
| 2025-09-30 | -56.97% |
| 2025-06-30 | -57.84% |
| 2025-03-31 | -63.38% |
| 2024-12-31 | -50.22% |
| 2024-09-30 | -52.50% |
| 2024-06-30 | -51.57% |
| 2024-03-31 | -51.31% |
| 2023-12-31 | -60.47% |
| 2023-09-30 | -53.54% |
| 2023-06-30 | -48.04% |
| 2023-03-31 | -53.85% |
| 2022-12-31 | -45.75% |
| 2022-09-30 | -46.87% |
| 2022-06-30 | -44.61% |
| 2022-03-31 | -61.87% |
| 2021-12-31 | -50.41% |
| 2021-09-30 | -52.72% |
| 2021-06-30 | -71.85% |
| 2021-03-31 | -51.49% |
| 2020-12-31 | -35.25% |
| 2020-09-30 | -25.24% |
| 2020-06-30 | -29.49% |
| 2020-03-31 | -76.25% |
| 2019-12-31 | -63.20% |
